We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Antibodies Now Available Directly From the Source
News

Antibodies Now Available Directly From the Source

Antibodies Now Available Directly From the Source
News

Antibodies Now Available Directly From the Source

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Antibodies Now Available Directly From the Source"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Monoclonal and polyclonal antibodies in lung and muscle development have recently been made available from Seven Hills Bioreagents (SHB), a venture of Cincinnati Children's Research Foundation (CCRF), directly from its web site

SHB claims that, because the reagents available from SHB are supplied by expert researchers who are actively using them in their own laboratories, SHB is able to provide unprecedented product support.

Dr. Clarissa Naftzger, an immunologist with extensive background in biotechnology, was hired in 2003 to spearhead this initiative.

"This is a novel initiative for our research institution that should directly benefit research programs at Cincinnati Children's Hospital while providing valuable tools to scientists throughout the world," Naftzger said.

"Many of the antibodies we’re now supplying directly have been sold through third parties for years," she added.

Additionally, a Scientific Advisory Board composed of leading scientists in the Cincinnati medical research community is providing guidance on the development of new products.

"This new enterprise is an alternative commercial strategy to traditional licensing agreements," said Joseph Fondacaro, Ph.D., Director of CCRF’s Office of Intellectual Property.

Advertisement